PharmaEssentia Invests $46M to Expand U.S. Manufacturing Footprint for BESREMi®
Introduction
PharmaEssentia Corporation has announced plans to establish a new wholly owned manufacturing subsidiary in Puerto Rico. The US$46 million investment aims to expand the production of BESREMi® (ropeginterferon alfa-2b) to meet growing demand, particularly in the United States.
Features:
The new facility will serve as a dedicated manufacturing centre for the U.S. market.
Puerto Rico offers a strong pharmaceutical ecosystem with skilled talent, advanced infrastructure, and regulatory expertise.
The investment will improve supply security, operational flexibility, and cost efficiency.
The facility will provide scalable manufacturing capacity to support future growth and potential new regulatory approvals for BESREMi®.
It is expected to secure supply and support long-term global growth of the product.
PharmaEssentia plans to obtain regulatory approval and begin operations at the Puerto Rico facility in 2027.
Specifications:
| Name | PharmaEssentia |
| Budget | $46 Million |
| Type | Construction |
| Year of Completion | 2027 |
